A Performance Study Comparing the EyeMirage (Test Device) to Standard of Care (Reference Device) in Patients 18 to 65 Years of Age Undergoing Standard Eye Examinations Such as Visual Acuity, Visual Field, Color Vision, and Self-Paced Saccade for Various Conditions
NCT ID: NCT06908967
Last Updated: 2025-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
160 participants
INTERVENTIONAL
2025-06-13
2025-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will be done in one visit to the eye clinic. Thirty days after the eye tests were done, participants will be called by the clinic for a general follow-up and to discuss any problems, if needed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
NCT02445313
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
NCT06934577
Artificial Intelligence-Aided Screening for Patients With Diabetic Retinopathy and Age-related Macular Degeneration in Family Medicine and Geriatric Medicine Outpatient Clinics
NCT07069647
Imaging of Vitreous Opacities in a Canadian Population
NCT06204848
Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study
NCT05963646
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SCREENING
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of Care
This Cohort will undergo assessments for visual acuity, visual field, color vision, and self-paced saccade first via the current standard of care tests and then using the EyeMirage device and app.
EyeMirage device
This is a novel, smartphone-based device powered by artificial intelligence that will be used for virtual and remote routine eye examinations.
EyeMirage
This Cohort will undergo assessments for visual acuity, visual field, color vision, and self-paced saccade first via the EyeMirage device and app, then via the standard of care tests.
EyeMirage device
This is a novel, smartphone-based device powered by artificial intelligence that will be used for virtual and remote routine eye examinations.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EyeMirage device
This is a novel, smartphone-based device powered by artificial intelligence that will be used for virtual and remote routine eye examinations.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male or female participants, 18 to 65 years of age at time of screening.
* Visual acuity of 20/200 or better.
* Willingness to comply with required screening procedures, eye assessments, and follow-up visits, if needed.
Exclusion Criteria
* Complete blindness or diffuse vision loss in either eye
* Clinical diagnosis of cognitive and motor diseases including but not limited to the following:
1. Neurodegenerative diseases such as dementia-like Alzheimer's disease, posterior cortical atrophy
2. Movement disorders such as Parkinson's disease and Parkinsonism tremors
3. Multiple sclerosis, stroke or any other neurological or physical conditions with paresis or plegia (i.e. weakness or paralysis of the limbs)
* Eyes with a spherical equivalent of greater than +9 or -9 diopters where the corrective lens is too large to fit in the headset.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Boniface Hospital
OTHER
St. Boniface Hospital Asper Clinical Research Institute
UNKNOWN
Neuroptek Corporation Inc.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bram Ramjiawan, PhD
Role: STUDY_DIRECTOR
St. Boniface Hospital Asper Clinical Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Boniface Eye Care Centre
Winnipeg, Manitoba, Canada
Brain, Vision and Concussion Clinic
Winnipeg, Manitoba, Canada
Prairie Eye Care (Northgate)
Winnipeg, Manitoba, Canada
Armstrong + Small Eye Care Centre
Winnipeg, Manitoba, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N001
Identifier Type: OTHER
Identifier Source: secondary_id
HS26606 (B2024:096)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.